Merit Medical Systems Earnings Call: Key Takeaways
Merit Medical delivered a strong Q3 2026 beat, raising full-year guidance driven by 9% organic growth and significant operating margin expansion despite gross margin headwinds.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Merit Medical Systems Inc filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts with these filters
Merit Medical delivered a strong Q3 2026 beat, raising full-year guidance driven by 9% organic growth and significant operating margin expansion despite gross margin headwinds.
Merit Medical Systems reported net sales of $1.22 billion for the nine months ended September 30, 2026, representing an 8.5% increase over the prior year. Net income for the same period rose significantly to $122.1 million, up from $90.5 million in 2025, driven by improved gross margins and controlled operating expenses.
Merit Medical Systems reported Q3 2026 financial results with 8.4% revenue growth and raised its full-year 2026 guidance. The company also disclosed the $45 million cash acquisition of Solo Pace, Inc., which was completed on October 13, 2026.
“Merit delivered third quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture.”
Martha G. Aronson, Merit’s President and CEO
“We have raised our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first nine months of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year.”
Martha G. Aronson, Merit’s President and CEO